Format

Send to

Choose Destination
Oncoimmunology. 2013 Jan 1;2(1):e22615.

NKT cell adjuvants in therapeutic vaccines against hematological cancers.

Author information

1
Cancer Immunology Program; Peter MacCallum Cancer Centre; East Melbourne, Victoria, Australia ; The University of Queensland Diamantina Institute; Princess Alexandra Hospital; Woolloongabba, Queensland, Australia.

Abstract

Immune adjuvants aimed at initiating or re-activating host immunity against poorly immunogenic cancers represent a potential tool for immunotherapy. By employing the natural killer T (NKT) cell agonist α-galactosylceramide in a whole tumor cell therapeutic vaccine approach, we have achieved potent suppression of established hematological cancers upon the elicitation of innate and adaptive antitumor immunity.

KEYWORDS:

NKT cells; hematological malignancies; immune adjuvants; immunotherapy; tumor vaccine; α-galactosylceramide

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center